Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
Bader P, Niemeyer C, Willasch A, Kreyenberg H, Strahm B, Kremens B, Gruhn B, Dilloo D, Vormoor J, Lang P, Niethammer D, Klingebiel T, Beck JF. Bader P, et al. Among authors: willasch a. Br J Haematol. 2005 Mar;128(5):649-58. doi: 10.1111/j.1365-2141.2004.05354.x. Br J Haematol. 2005. PMID: 15725087 Free article. Clinical Trial.
Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism-high informativity and sensitivity as well as excellent reproducibility and precision of measurement.
Willasch A, Schneider G, Reincke BS, Shayegi N, Kreyenberg H, Kuci S, Weber G, Van Der Reijden B, Niethammer D, Klingebiel T, Bader P. Willasch A, et al. Lab Hematol. 2007;13(3):73-84. doi: 10.1532/LH96.07004. Lab Hematol. 2007. PMID: 17984038
Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A; ALL-REZ BFM Study Group. Bader P, et al. Among authors: willasch a. J Clin Oncol. 2009 Jan 20;27(3):377-84. doi: 10.1200/JCO.2008.17.6065. Epub 2008 Dec 8. J Clin Oncol. 2009. PMID: 19064980
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, Steinbach D, Weber G, Hollink IH, Zwaan CM, Biondi A, van der Velden VH, Reinhardt D, Cazzaniga G, Bader P, Trka J; European Study Group on WT1 Expression in Childhood AML. Willasch AM, et al. Leukemia. 2009 Aug;23(8):1472-9. doi: 10.1038/leu.2009.51. Epub 2009 Mar 26. Leukemia. 2009. PMID: 19322206
Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation.
Kreyenberg H, Eckert C, Yarkin Y, Reising M, Willasch A, Handgretinger R, Kremens B, von Stackelberg A, Henze G, Klingebiel T, Bader P. Kreyenberg H, et al. Among authors: willasch a. Leukemia. 2009 Jul;23(7):1355-8. doi: 10.1038/leu.2009.72. Epub 2009 Apr 9. Leukemia. 2009. PMID: 19357703 No abstract available.
69 results